<!-- Page: 1 -->

# AI-Powered Small Molecule Discovery
Accelerating CNS-Penetrant Therapeutics through Deep Learning

## The Challenge: The Blood-Brain Barrier Gap

![image](https://static-us-img.skywork.ai/prod/nexus/1766446252/cropped_image_2_1766446252715525377.jpg)

![image](https://static-us-img.skywork.ai/prod/nexus/1766446252/cropped_image_3_1766446252716286435.jpg)

## of small molecules
excluded by BBB

Low hit rates from traditional screening

Late-stage failure due to toxicity

![image](https://static-us-img.skywork.ai/prod/nexus/1766446252/cropped_image_7_1766446252720935203.jpg)

## Methodology: The AI Filtration Pipeline

![image](https://static-us-img.skywork.ai/prod/nexus/1766446252/cropped_image_9_1766446252745477197.jpg)

> AI-Driven Discovery: De-Risking through Virtual Screening & Predictive Modeling

## Results: MSH3 Pilot for Huntington's Disease

![image](https://static-us-img.skywork.ai/prod/nexus/1766446252/cropped_image_12_1766446252750201149.jpg)

## Days vs. Months
timeline reduction

![image](https://static-us-img.skywork.ai/prod/nexus/1766446252/cropped_image_14_1766446252751560343.jpg)

![image](https://static-us-img.skywork.ai/prod/nexus/1766446252/cropped_image_15_1766446252752275387.jpg)

Sub-10 nM
potency achieved

![image](https://static-us-img.skywork.ai/prod/nexus/1766446252/cropped_image_17_1766446252753709089.jpg)

![image](https://static-us-img.skywork.ai/prod/nexus/1766446252/cropped_image_18_1766446252759480972.jpg)

Identified 66 Potential Small Molecule Candidates

## • Identified CNS-viable

leads with optimal molecular weight, lipophilicity, and TPSA profiles

• MSH3 pilot successfully completed

## Impact: Shifting the Discovery Paradigm

![image](https://static-us-img.skywork.ai/prod/nexus/1766446252/cropped_image_24_1766446252765776911.jpg)

## Speed

![image](https://static-us-img.skywork.ai/prod/nexus/1766446252/cropped_image_26_1766446252766597135.jpg)

Rapid identification of CNS-
active therapeutics for urgent
unmet neurological needs.

## De-Risked Pipelines

![image](https://static-us-img.skywork.ai/prod/nexus/1766446252/cropped_image_29_1766446252770098875.jpg)

Early-stage ADMET filtering significantly reduces late-stage clinical attrition.

## Scalability

Scale across multiple
neurodegenerative disease
programs simultaneously.

Transforming the Pace and Success Rate of CNS Drug Development through AI-Integrated Platforms

今

ALEXION

BioClarityAI